For the year ending 2025-12-31, FBLG had -$9,091K decrease in cash & cash equivalents over the period. -$16,656K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -18,646 |
| Change in fair value of warrant liability | 0 |
| Change in fair value of forward contract liability | 0 |
| Change in fair value of sepa put option liability | 352 |
| Change in fair value of convertible debt | -1,773 |
| Commitment fee expense | 0 |
| Gain on termination of warrant and commitment fee liabilities | 0 |
| Non-cash discount on convertible debt | 625 |
| Stock-based compensation expense | 2,686 |
| Amortization of operating lease right-of-use asset | 588 |
| Depreciation expense | 244 |
| Prepaid expenses | 1,230 |
| Accounts payable and accrued expenses | -1,502 |
| Other current assets | -18 |
| Other assets | 48 |
| Payable to parent | 0 |
| Operating lease liability | -550 |
| Net cash used in operating activities | -16,394 |
| Purchases of property and equipment | 262 |
| Net cash used in investing activities | -262 |
| Proceeds from short-term convertible debt | 4,375 |
| Proceeds from short-term borrowing | 0 |
| Repayments of short-term borrowing | 0 |
| Repayments of short-term convertible debt | 3,400 |
| Proceeds from issuance of common stock, net of direct costs | 6,590 |
| Net cash provided by financing activities | 7,565 |
| Net decrease in cash and cash equivalents | -9,091 |
| Cash and cash equivalents, beginning of year | 13,985 |
| Cash and cash equivalents, end of year | 4,894 |
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)